Thermoresponsive Polymer PRP Composition for Erectile Dysfunction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for erectile dysfunction, such as phosphodiesterase type-5 inhibitors and intracavernous injections, often result in side effects and unsatisfactory outcomes, and there is a need for a curative treatment that provides sustained release of growth factors to promote tissue regeneration.

Innovation Solution

A therapeutic composition comprising platelet-rich plasma (PRP) or a growth factor concentrate derived from PRP, combined with a thermoresponsive polymer, which is administered to enhance retention and sustained release of growth factors at the site of injection, improving erectile function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If phosphodiesterase type-5 inhibitors are used to treat erectile dysfunction, then erectile function is improved, but side effects increase

Engineering Contradiction:

Improveerectile functionVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and utilizes endogenous growth factors (PDGF, TGF-β, VEGF, FGF) naturally present in platelet-rich plasma to treat erectile dysfunction, replacing exogenous pharmaceutical agents like PDE5 inhibitors that cause side effects. This extraction of beneficial biological factors from the patient's own blood provides therapeutic effect without introducing harmful external substances.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The therapy utilizes the patient's own autologous blood to generate platelet-rich plasma containing growth factors that promote tissue regeneration and repair. The body's own biological systems are harnessed to treat the condition, eliminating the need for external pharmaceuticals and their associated side effects.

Inventive Principle:

Principle #25Self-service

2Quantity of substance

If growth factors are released immediately after injection, then initial concentration is high, but duration of action is short

Engineering Contradiction:

Improvegrowth factor concentrationVSAvoidduration of growth factor release

Core Design Contradiction:

Quantity of substanceVSDuration of action of moving object

Solution Approach 1:

The patent prepares platelet-rich plasma in advance where growth factors are concentrated within platelets before injection. The platelets serve as pre-loaded reservoirs that will release factors at the target site, ensuring both high initial concentration and sustained release over time rather than immediate complete release.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent achieves continuous therapeutic action through the sustained release mechanism of platelet-rich plasma. As platelets gradually degranulate at the injection site, growth factors are released continuously over an extended period, maintaining therapeutic concentrations and promoting ongoing tissue regeneration without interruption.

Inventive Principle:

Principle #20Continuity of useful action

3Reliability

If stem cells are injected to promote tissue regeneration, then regenerative effect is achieved, but treatment complexity increases

Engineering Contradiction:

Improvetissue regenerationVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines platelet-rich plasma therapy with stem cell injection into a single integrated treatment approach. The platelet-rich plasma provides growth factors that enhance stem cell survival, proliferation, and differentiation, creating a synergistic effect that improves tissue regeneration while managing complexity through coordinated delivery of both therapeutic elements.

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition provides a higher and more sustained improvement in erectile function compared to existing treatments, reducing side effects and enhancing tissue regeneration by maintaining growth factor levels for a longer duration.

Implementation Method 1

a thermoresponsive polymer, which is administered to enhance retention and sustained release of growth factors at the site of injection

Methodology Applied

Scientific EffectThermoresponsive phase transition: Phase Change

Data Source

PatentUS20220395558A1Compositions for treatment of erectile dysfunction, methods for preparing the same and applications thereof

Publication Date: 2022.12.15 PALANIVEL VASANTHI

AI summary

The present disclosure generally relates to the field of infertility, and in particular male infertility. Accordingly, the present disclosure provides for compositions and methods for managing male infertility, caused by erectile dysfunction. More particularly, the present disclosure provides a therapeutic composition comprising a platelet rich plasma (PRP) or a growth factor concentrate derived therefrom and a thermoresponsive polymer. The present disclosure also relates to the compositions of PRP and the concentrate themselves. Consequently, methods to obtain the said compositions, along with therapeutic applications for treatment of erectile dysfunction are also provided.